Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation

SAN DIEGO, CA--(Marketwired - September 22, 2016) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,446,134 providing non-invasive metered nasal spray delivery of octreotide. Currently, octreotide is administered by injection three times per day or in a long acting injectable form to treat acromegaly, flushing episodes and watery diarrhea caused by cancerous tumors (carcinoid syndrome or VIP adenomas). The long acting injectable forms, which are typically administered by healthcare professionals, are associated with pain and irritation at the injection site. According to a comprehensive discussion of current practices of octreotide administration that appeared in BioCentury, Feb. 18, 2013, pp. A8-A9, the long acting forms of octreotide "are administered with large-bore needles that penetrate up to two inches beneath the skin and remain in place 45-120 seconds to deliver the dose, causing pain and discomfort during and long after the injection."

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where a non-invasive (i.e., non-injectable) form of the drug is unavailable or where speed of onset is important, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis licenses its patented Intravail® non-invasive delivery and ProTek® protein stabilization technologies to pharma companies worldwide. Aegis' licensees include seven of the top 10 largest pharmaceutical companies and two of the top 10 largest multinational generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than seventy-five issued and pending drug formulation patents covering noninvasive delivery and stabilization of biotherapeutics, biosimilars, and small-molecule drugs.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage and anaphylaxis caused by polysorbate surfactants.

For more information about Aegis, please visit: http://www.aegisthera.com.